About Celeris Therapeutics
Celeris Therapeutics is a company based in Graz (Austria) founded in 2020 by Christopher Trummer and Jakob Hohenberger. Celeris Therapeutics has raised $4.4 million across 2 funding rounds from investors including i&i Bio, Pace Ventures and APEX Ventures. Celeris Therapeutics operates in a competitive market with competitors including Relay Therapeutics, Atomwise, Genesis Therapeutics, Unnatural Products and neoX Biotech, among others.
- Headquarter Graz, Austria
- Founders Christopher Trummer, Jakob Hohenberger
-
Sectors
Healthcare
-
Phone
Locked
-
Website
Locked
-
Social
Locked
-
Annual Revenue
Not available
-
Net Profit
Not available
-
EBITDA
Not available
-
Total Equity Funding
$4.4 M (USD)
in 2 rounds
-
Latest Funding Round
$4.4 M (USD), Seed
Feb 10, 2022
-
Investors
i&i Bio
& 4 more
-
Employee Count
Not available
Unlock complete access to The Company Check
Get unrestricted viewing across everything we track — from companies and brands to investors, funding rounds, acquisitions, financials, and more.
- Unlimited viewing on all profiles Companies, investors, financials, funding, acquisitions & directors
- Full access to every database India & global coverage, advanced filters and rich profile details
- Always-on access from your team account Single premium plan for everything you see on the portal
People of Celeris Therapeutics
Unlock access to complete
Funding Insights of Celeris Therapeutics
Celeris Therapeutics has successfully raised a total of $4.4M across 2 strategic funding rounds. The most recent funding activity was a Seed round of $4.4 million completed in February 2022. This substantial capital infusion reflects strong investor confidence in the company's business model, growth potential, and market opportunities. The funding enables strategic expansion, product development, market penetration, and operational scaling to drive long-term value creation and competitive advantage.
Investors in Celeris Therapeutics
Celeris Therapeutics has secured backing from 5 investors, including venture fund investors. Prominent investors backing the company include i&i Bio, Pace Ventures and APEX Ventures.
| Investor | Description | Founded Year | Domain | Location |
|---|---|---|---|---|
|
-
|
Locked | Locked | Locked | |
|
Early-stage venture capital investments are made by Pace Ventures.
|
Locked | Locked | Locked | |
|
Venture capital funding is offered for deep-tech and medical startups.
|
Locked | Locked | Locked |
Investor details for Celeris Therapeutics
Investor domains, locations, round participation, and complete history require an active premium plan.
- Investor domains
- Investor locations
- Funding rounds
- Participation history
Verified entity values are shown only after access is granted.
Investments & Acquisitions by Celeris Therapeutics
Investment portfolio details for Celeris Therapeutics
Portfolio company identities, transaction dates, round details, and investment values require an active premium plan.
- Portfolio identities
- Transaction dates
- Round details
- Investment values
Verified entity values are shown only after access is granted.
Financial Statements - Celeris Therapeutics
Detailed financials for Celeris Therapeutics
Historical revenue, profit, statement rows, ratios, and trend charts require an active premium plan.
- Historical revenue
- Profit trends
- Statement rows
- Financial ratios
Verified entity values are shown only after access is granted.
Celeris Therapeutics Comparisons
Peer comparison for Celeris Therapeutics
Named peer metrics, headcount, funding, location, and side-by-side benchmarks require an active premium plan.
- Named peers
- Headcount comparison
- Funding comparison
- Operating benchmarks
Verified entity values are shown only after access is granted.
Competitors of Celeris Therapeutics
Celeris Therapeutics operates in a dynamic and competitive business environment, facing competition from various established players and emerging companies in the market. The competitive landscape includes prominent companies such as Relay Therapeutics, Atomwise, Genesis Therapeutics, Unnatural Products and neoX Biotech, among others.
| Company Name | Domain | Founded year | HQ Location | Description |
|---|---|---|---|---|
| Locked | Locked | Locked |
Drug discovery platform is developed to study protein motion.
|
|
| Locked | Locked | Locked |
AI-driven platform for structure-based drug discovery is provided.
|
|
| Locked | Locked | Locked |
Computational platform for AI-driven small molecule drug discovery is developed.
|
|
| Locked | Locked | Locked |
Peptides are engineered via computational biology for undruggable targets.
|
|
| Locked | Locked | Locked |
Protein-protein interactions are researched and characterized to aid drug discovery.
|
Detailed competitors of Celeris Therapeutics
Competitor domains, locations, full profiles, and operating metrics require an active premium plan.
- Domains and locations
- Full company profiles
- Operating metrics
- Competitive positioning
Verified entity values are shown only after access is granted.
Latest news on Celeris Therapeutics
Complete news archive for Celeris Therapeutics
Full article history, source details, and older brand coverage require an active premium plan.
- Full article archive
- Source and publication date
- Older coverage
- Brand-specific news history
Verified entity values are shown only after access is granted.
Frequently Asked Questions about Celeris Therapeutics
Celeris Therapeutics was founded in 2020 and raised its 1st funding round 1 year after it was founded.
Celeris Therapeutics is headquartered in Graz, Austria. It is registered at Graz, Styria, Austria.
Christopher Trummer is the current CEO of Celeris Therapeutics. They have also founded this company.
Celeris Therapeutics is a funded company, having raised a total of $4.4M across 2 funding rounds to date.
Celeris Therapeutics was founded in 2020 in Graz, Austria, within the biotechnology sector. An AI-driven platform is utilized by the company to enable degradation of undruggable protein targets through methods such as PROTACs and molecular glues. Operations involve computer-based drug design and discovery, supported by the One cloud platform, which facilitates targeted therapeutic development for specific biological challenges.
Celeris Therapeutics's top competitors include Atomwise, Genesis Therapeutics and Unnatural Products.
Celeris Therapeutics has 5 investors. Key investors include i&i Bio, Pace Ventures, APEX Ventures, R42 Group, and Longevitytech.fund.